Assessment of Early Changes in SD-OCT After Initiation of a Treatment by Intravitreal Aflibercept (EYLEA®)START

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Neovascular Age-related Macular Degeneration of All Subtypes
Interventions
PROCEDURE

Intravitreal injection

2 mg intravitreal Aflibercept initiated with one injection every 4 weeks for three consecutive doses (loading dose) The duration of the follow-up is 12 weeks. This means 3 injections per patient should be given over the study period

Trial Locations (10)

21079

Service Ophtalmologie CHU DIJON 14 rue Gaffarel BP 77908, Dijon

37000

Centre Ophtalmologie Transparence 30 Boulevard Heurteloup, Tours

44093

Sce Ophtalmologie CHU Nantes 1 place Alexis Ricordeau, Nantes

45200

Cabinet d'ophtalmologie 1 rue Pougin de la Maisonneuve, Montargis

69317

Service d'Ophtalmologie Hôpital de la croix rousse, Lyon

75011

Centre ophtalmique d'imagerie et de laser (CIL) 11 rue Antoine Bourdelle, Paris

75019

Sce du Pr SAHEL Fondation ROTHSCHILD 25 rue Manin, Paris

75475

Sce Ophtalmologie Hôpital Lariboisière 2 rue Ambroise Paré, Paris

76100

Service Opthalmo 2 Clinique Mathilde 4 rue de Lessard, Rouen

94000

Service d'ophtalmologie Hôpital Henri Mondor 40, avenue de Verdun, Créteil

All Listed Sponsors
lead

University Hospital, Bordeaux

OTHER

NCT02246829 - Assessment of Early Changes in SD-OCT After Initiation of a Treatment by Intravitreal Aflibercept (EYLEA®)START | Biotech Hunter | Biotech Hunter